![]() |
| Site Navigation |
Follicular Lymphomas |
|
|
|
| Follicular lymphomas (or more formally
speaking, follicular center cell lymphomas with a follicular growth pattern) are one of
the more common non-Hodgkin's lymphomas in North America. They afflict almost exclusively
adults, particularly the middle-aged and elderly. They are of B-cell
lymphocyte origin. Because the small-cleaved cells of follicular lymphomas know how to
circulate in the blood, patients usually present with disseminated lymphadenopathy
(lymphoma in multiple parts of the body). Nonetheless these lymphomas have a better
prognosis than higher grade lymphomas. Causes
Most cases of follicular lymphoma, especially those rich in small-cleaved cells, have a t(14;18) gene translocation. This results in a rearranged and constitutively over-expressed gene called BCL-2. |
|||
|
|
|||
|
Follicular lymphomas are divided into 3 types according to the ratio of small-cleaved
and large cells: 2. Mixed small-cleaved and large cell type has between 20-25% and 50% large
cells or between 5 and 15 large cells per high 3. Large cell type has more than 50% large cells, or more than 15 large cells per high power field. Large cell lymphomas with a follicular growth pattern are uncommon, and the nodularity can be hard to perceive. These lymphomas are the only intermediate grade follicular lymphomas - they are classified as indolent but their aggressive nature is noted by NCI. Treatment Treatment options depend on the stage and grade of the disease. The infrequent adult patients with early-stage disease may be treated with local radiation, with or without chemotherapy. Patients with more advanced but low-grade disease may remain untreated as long as no symptoms or lymphoma-related organ compromise are present (watch and wait). When treatment becomes necessary, the options include: Cytotoxic T-lymphocytes (CTL), also known as “killer” T-cells, are also an important component of the immune system and specifically directing these immune cells to fight lymphoma cells by gene therapy is an emerging technology. Genetically modified CTL can recognize lymphoma cells like a monoclonal antibody, but then attack the lymphoma cells like a “killer” T-cell. At the Fred Hutchinson Cancer Research Center in Seattle, lymphoma researchers have started using this gene therapy approach following chemotherapy to treat patients with relapsed follicular non-Hodgkin’s lymphoma. For more information about this study, call +1-206-667-5184 or go to http://www.fhcrc.org/cancer_info/studies/1503.html Further Reading Non-Hodgkin's Lymphomas, Peter M. Mauch (Editor), James O. Armitage (Editor), et al., 2004. Web Sites
Survivor Sites
Mailing Lists
Reference Sources
Non-Hodgkin's Lymphoma Information Pages: Non-Hodgkin's
Lymphomas Childhood Lymphoma Information Pages: Childhood
Lymphoma Home - Gateway to Support and More The Lymphoma Information Network This page is a work in progress - if you have more complete information, references, or other information please contact the author. The author is not in the medical field and does not warrant the correctness of the material on this page or the sites linked - please take online information and consult with your own medical team to make informed decisions. Copyright © 1998-2006 Lymphoma Information
Network - All Rights Reserved |
|||